The RNA Phase III cohort contains 10 trials, 335 site-trial slots, 257 distinct European sites, and 1,060 planned country-level participant allocations. Uniwersyteckie Centrum Kliniczne is the clearest site leader, appearing in 5 of 10 trials. Country capacity is concentrated in Spain, Germany, Italy, France, and Poland, which together account for 207 of 335 site slots.
Uniwersyteckie Centrum Kliniczne leads with 5 trial participations, covering 50.0% of the 10-trial cohort. The next sites shown each appear in 3 of 10 trials, or 30.0% of the cohort.
| Rank | Site | Country | Trials | Share |
|---|---|---|---|---|
| 1 | Uniwersyteckie Centrum Kliniczne | Poland | 5 | 50.0% |
| 2 | Amsterdam UMC Stichting | Netherlands | 3 | 30.0% |
| 3 | Assistance Publique Hopitaux De Paris | France | 3 | 30.0% |
| 4 | Centre Hospitalier Regional De Marseille | France | 3 | 30.0% |
| 5 | Centre Hospitalier Regional Universitaire De Tours | France | 3 | 30.0% |
| 6 | Centre Hospitalier Universitaire De Caen Normandie | France | 3 | 30.0% |
| 7 | Cliniques Universitaires Saint-Luc | Belgium | 3 | 30.0% |
| 8 | Fondation IRCCS Istituto Nazionale Dei Tumori | Italy | 3 | 30.0% |
| 9 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Italy | 3 | 30.0% |
| 10 | Goethe University Frankfurt | Germany | 3 | 30.0% |
Poland has the single strongest repeat-site signal through Uniwersyteckie Centrum Kliniczne, while France contributes several repeat-capable hospital networks. For RNA Phase III feasibility, the leading site pattern is less about one dominant country and more about a distributed network of repeat oncology, cardiology, and rare-disease centers.
The top five countries account for 207 of 335 site slots, or 61.8% of all RNA Phase III site activity. Spain leads by site footprint with 48 of 335 site slots, while Poland is nearly tied for participant allocation with 144 of 1,060 planned country-level participants.
| Country | Site slots | Participants | Trial-country entries |
|---|---|---|---|
| Spain | 48 | 145 | 8 |
| Germany | 42 | 135 | 7 |
| Italy | 40 | 128 | 7 |
| France | 39 | 127 | 8 |
| Poland | 38 | 144 | 7 |
Spain, Germany, Italy, France, and Poland form the operational core of European RNA Phase III execution. The close spread between these five countries suggests sponsors are using broad multi-country networks rather than relying on a single dominant national market.
Oncology accounts for 5 of 10 trials, but it contributes 254 of 335 site slots and 942 of 1,060 participant allocations. This means oncology represents 75.8% of site activity and 88.9% of planned participant allocation in the Phase III RNA cohort.
Late-stage RNA activity is not evenly distributed across clinical domains. Oncology is the main capacity driver, indicating that RNA site feasibility in Phase III is currently shaped most by oncology networks, imaging/response assessment workflows, and large multinational patient-enrolment plans.
Non-small cell lung cancer is the largest disease label in the oncology subset, with 164 site slots across 2 trials. In cardiology, heterozygous familial hypercholesterolemia contributes 35 of 42 cardiology site slots, while hereditary angioedema contributes 22 of 30 rare-disease site slots.
RNA Phase III site demand is disease-clustered rather than broadly spread. Non-small cell lung cancer is the largest operational driver, while rare-disease and cardiology RNA programs use smaller but highly specialized site networks.
The cohort includes 7 pure Phase III trials and 3 Phase II/III trials. RNA modality tags show 6 of 10 trials with mRNA and 5 of 10 with Other RNA; combination tagging is common, including monoclonal antibody tags in 5 of 10 trials and small-molecule tags in 3 of 10 trials.
The site network is not limited to standalone RNA products. Many trials combine RNA modality tags with antibody or small-molecule modalities, so late-stage RNA execution often requires sites capable of managing combination-treatment protocols and complex specialty workflows.
Site-trial slot means one de-duplicated site listed for one trial in one country. Participant allocation means the country-level planned participant number reported in the geography variable. RNA includes trials matched to mRNA or Other RNA modality tags. Phase III cohort includes records in the Phase III files, including trials whose trial-stage field is Phase II/III.